Skip to main content
Sinocelltech Group Limited logo

Sinocelltech Group Limited — Investor Relations & Filings

Ticker · 688520 ISIN · CNE100003ZL3 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 659 across all filing types
Latest filing 2024-10-28 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 688520

About Sinocelltech Group Limited

https://www.sinocelltech.com/

Sinocelltech Group Limited focuses on the research, development, and commercialization of innovative biologics, including monoclonal antibodies, recombinant proteins, and vaccine candidates. The company's product pipeline addresses therapeutic areas such as oncology, autoimmune disorders, hematology, and infectious diseases. Key offerings include recombinant human coagulation factor VIII for hemophilia A and a range of biosimilars. Sinocelltech leverages an integrated technology platform encompassing early-stage discovery through to large-scale industrial production. This infrastructure supports the development of high-quality biological medicines aimed at addressing unmet medical needs through advanced protein engineering and cell line development.

Recent filings

Filing Released Lang Actions
神州细胞2024年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '北京神州细胞生物技术集团股份公司 2024 年第三季度报告' which translates to 'Beijing Shenzhou Cell Biotechnology Group Co., Ltd. 2024 Third Quarter Report'. It contains detailed financial data including income statement, balance sheet, cash flow statement, and notes for the third quarter of 2024. The document explicitly states it is a quarterly report and includes unaudited financial statements for the period ending September 30, 2024. The length of the document (13,327 characters) and the presence of comprehensive financial data confirm it is a full interim/quarterly report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). 9M 2024
2024-10-28 Chinese
神州细胞自愿披露关于控股子公司重组呼吸道合胞病毒疫苗SCTV02获得药物临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by Beijing Shenzhou Cell Biotechnology Group Co., Ltd. regarding the approval of a clinical trial for a recombinant respiratory syncytial virus vaccine (SCTV02) by the National Medical Products Administration. It contains no financial data, no detailed financial statements, nor any report-like content. The document is short (1300 characters) and serves as a regulatory announcement about a clinical trial approval, including risk warnings and product information. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is not a certification or officer attestation. It is a regulatory announcement about a clinical trial approval, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2024-10-22 Chinese
中信证券股份有限公司关于北京神州细胞生物技术集团股份公司2024半年度持续督导跟踪报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2024 半年度持续督导跟踪报告" (2024 Semi-Annual Continuous Supervision Follow-up Report) issued by the sponsor (中信证券股份有限公司) for 北京神州细胞生物技术集团股份公司. It references regulatory requirements under the Shanghai Stock Exchange Sci-Tech Innovation Board rules and details ongoing supervision activities, risk assessments, financial data for the first half of 2024, and R&D progress. The document contains substantive financial data and detailed management commentary on business risks, financial performance, and operational updates for a half-year period. This matches the characteristics of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year and includes actual financial statements and analysis. It is not merely an announcement or certification, nor is it a full annual report or earnings release. Therefore, the correct classification is IR with high confidence. H1 2024
2024-09-11 Chinese
神州细胞关于参加2024年半年度制药及生物制品专场集体业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement from Beijing Sinocell Technology Group Co., Ltd. about participating in a 2024 semi-annual pharmaceutical and biological products collective performance explanation meeting. It mentions the company has already disclosed its 2024 semi-annual report on August 22, 2024, and this event is to facilitate investor understanding through an online interactive session. The document does not contain actual financial statements or detailed financial data but rather informs about the upcoming investor presentation and how investors can participate and submit questions. The document length is short (1364 characters), and it serves as a notice for an investor presentation event rather than the report itself. Therefore, it fits best under Investor Presentation (IP).
2024-09-06 Chinese
神州细胞2024年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement from the 2024 second extraordinary shareholders' meeting of Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It details the meeting date, attendance, voting results on various proposals including perpetual debt financing and board changes, and includes legal witness statements confirming the legality of the meeting and voting process. The content focuses on official voting results from a shareholders' meeting rather than the meeting materials or presentations themselves. The document length is 2385 characters, which is relatively short and consistent with a voting results announcement rather than a full report or presentation. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2024-09-06 Chinese
北京市金杜律师事务所关于北京神州细胞生物技术集团股份公司2024年第二次临时股东大会的法律意见书
Regulatory Filings
2024-09-06 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.